Ligand Pharmaceuticals Inc (LGND): Melanie J Herman , Director of Accounting of Ligand Pharmaceuticals Inc sold 334 shares on May 18, 2016. The Insider selling transaction was reported by the company on May 19, 2016 to the Securities and Exchange Commission. The shares were sold at $120.50 per share for a total value of $40,247.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 9, 2016, Jason Aryeh (director) sold 25,000 shares at $119.37 per share price.On May 3, 2016, John W Kozarich (director) sold 1,000 shares at $121.75 per share price.Also, On Mar 17, 2016, Matthew W Foehr (President and COO) sold 6,400 shares at $96.70 per share price.On Mar 9, 2016, John L Higgins (Chief Executive Officer) sold 10,833 shares at $102.71 per share price.
Shares of Ligand Pharmaceuticals (LGND) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -3.16 points or -2.63% at $117.17 with 2,90,617 shares getting traded. Post opening the session at $119.59, the shares hit an intraday low of $114.77 and an intraday high of $121.3 and the price vacillated in this range throughout the day. The company has a market cap of $2,440 M and the number of outstanding shares has been calculated to be 2,08,22,444 shares. The 52-week high of Ligand Pharmaceuticals is $131.84 and the 52-week low is $71.63.
Company has been under the radar of several Street Analysts.Ligand Pharmaceuticals is Initiated by Sidoti to Buy. The Rating was issued on Mar 11, 2016.Ligand Pharmaceuticals is Initiated by H.C. Wainwright to Buy and the brokerage firm has set the Price Target at $146. The Rating was issued on Mar 3, 2016.
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Company’s technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases such as hepatitis multiple myeloma muscle wasting Alzheimers disease dyslipidemia diabetes anemia epilepsy focal segmental glomerulosclerosis (FSGS) and osteoporosis.